Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$1.38B |
| 2 |
Microsoft
MSFT
|
+$1.13B |
| 3 |
Amazon
AMZN
|
+$756M |
| 4 |
Tesla
TSLA
|
+$466M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
XLNX
Xilinx Inc
XLNX
|
+$199M |
| 2 |
INFO
IHS Markit Ltd. Common Shares
INFO
|
+$191M |
| 3 |
NUAN
Nuance Communications, Inc.
NUAN
|
+$62.8M |
| 4 |
KL
Kirkland Lake Gold Ltd Ordinary
KL
|
+$43.9M |
| 5 |
ATH
Athene Holding Ltd. Class A Common Shares
ATH
|
+$42.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.22% |
| 2 | Healthcare | 14.23% |
| 3 | Consumer Discretionary | 13.07% |
| 4 | Communication Services | 9.53% |
| 5 | Industrials | 8.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GATO
2626
DELISTED
Gatos Silver, Inc.
GATO
| $423K | ﹤0.01% |
98,000
+6,900
| +8% | +$38K |
|
2627
UroGen Pharma
URGN
$2.39B
| $417K | ﹤0.01% |
47,900
+4,000
| +9% | +$31.2K |
|
2628
XBiotech
XBIT
$75M
| $404K | ﹤0.01% |
46,800
+3,800
| +9% | +$38.1K |
|
2629
Evolv Technologies
EVLV
$1.03B
| $401K | ﹤0.01% |
151,500
+8,800
| +6% | +$28.8K |
|
2630
CEL-SCI Corp
CVM
$25.9M
| $400K | ﹤0.01% |
3,390
+233
| +7% | +$37.9K |
|
2631
Telos
TLS
$324M
| $394K | ﹤0.01% |
39,500
+3,200
| +9% | +$35.9K |
|
2632
Curis
CRIS
$3.49M
| $387K | ﹤0.01% |
406
+29
| +8% | +$37K |
|
2633
Monte Rosa Therapeutics
GLUE
$1.36B
| $386K | ﹤0.01% |
27,500
+1,900
| +7% | +$26.4K |
|
|
GAN
2634
DELISTED
GAN Ltd
GAN
| $385K | ﹤0.01% |
79,900
+5,600
| +8% | +$36K |
|
2635
Cullinan Oncology
CGEM
$1.26B
| $379K | ﹤0.01% |
36,200
+2,700
| +8% | +$36.5K |
|
2636
Rekor Systems
REKR
$94M
| $379K | ﹤0.01% |
83,200
+6,000
| +8% | +$28.2K |
|
2637
SelectQuote
SLQT
$124M
| $379K | ﹤0.01% |
135,700
+10,000
| +8% | +$48.2K |
|
|
EPZM
2638
DELISTED
Epizyme, Inc
EPZM
| $376K | ﹤0.01% |
327,100
+170,100
| +108% | +$277K |
|
|
NGMS
2639
DELISTED
NeoGames S.A. Ordinary Shares
NGMS
| $375K | ﹤0.01% |
24,300
+1,600
| +7% | +$33.5K |
|
2640
Aveanna Healthcare
AVAH
$1.97B
| $371K | ﹤0.01% |
108,800
+7,500
| +7% | +$40.7K |
|
|
CASA
2641
DELISTED
Casa Systems, Inc. Common Stock
CASA
| $368K | ﹤0.01% |
81,400
+7,300
| +10% | +$33.2K |
|
2642
Momentus
MNTS
$91.5M
| $365K | ﹤0.01% |
9
+1
| +13% | +$38.5K |
|
|
FMTX
2643
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $365K | ﹤0.01% |
39,300
+2,700
| +7% | +$28.7K |
|
|
HGEN
2644
DELISTED
HUMANIGEN, INC.
HGEN
| $363K | ﹤0.01% |
120,700
+16,100
| +15% | +$43.1K |
|
|
LTCH
2645
DELISTED
Latch, Inc. Common Stock
LTCH
| $359K | ﹤0.01% |
84,100
+6,300
| +8% | +$32.9K |
|
2646
Precision BioSciences
DTIL
$205M
| $354K | ﹤0.01% |
3,830
+333
| +10% | +$45.2K |
|
|
EPIX
2647
DELISTED
ESSA Pharma
EPIX
| $353K | ﹤0.01% |
57,200
+4,000
| +8% | +$35.2K |
|
2648
Root
ROOT
$748M
| $339K | ﹤0.01% |
9,572
+2,589
| +37% | +$93.3K |
|
|
ZYXI
2649
DELISTED
Zynex
ZYXI
| $338K | ﹤0.01% |
54,310
+3,600
| +7% | +$25.3K |
|
2650
The Honest Company
HNST
$544M
| $337K | ﹤0.01% |
64,600
+5,000
| +8% | +$30.1K |
|
Similar funds
Swiss National Bank's Q1 2022 Portfolio in Review
As of Q1 2022, Swiss National Bank held 2,722 positions worth $177B, up 6.8% from $166B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Swiss National Bank deployed $20.2B of net new capital in Q1 2022, opening 3 new positions and adding to 2,642 existing holdings. Its largest new stake was Constellation Energy: 1,411,783 shares worth $79.4M.
By sector, the portfolio is most concentrated in Technology at 28% of assets, down from 29% a quarter earlier, followed by Healthcare and Consumer Discretionary.
On the sell side, the largest reduction was Exelon, an estimated $41.2M trimmed.
- Swiss National Bank's largest Q1 2022 buy was Constellation Energy: 1,411,783 shares worth $79.4M.
- Swiss National Bank added most to Apple in Q1 2022, an estimated $1.38B increase.
- Swiss National Bank's biggest Q1 2022 reduction was Exelon, cutting an estimated $41.2M.
- Swiss National Bank fully exited Xilinx Inc in Q1 2022, selling an estimated $199M.
- Swiss National Bank's ten largest holdings make up 28% of its $177B portfolio in Q1 2022.
- Swiss National Bank opened 3 new positions and closed 31 in Q1 2022.
- Swiss National Bank's portfolio value rose 6.8% quarter-over-quarter to $177B.
Based on Swiss National Bank's 13F filing for Q1 2022, filed 9 May 2022.